According to some studies, between 66 and 84 percent of women with anorexia nervosa don’t get their periods, and between 6 and 11 percent have irregular cycles. However, low BMD may not be completely reversible with weight restoration and restoration of menses, particularly for those patients who did not achieve their peak bone mass during adolescence. It is important to be realistic with patients that the deleterious effects of AN on BMD may not be completely reversible with weight restoration and restoration of menses, particularly for those patients who did not achieve their peak bone mass during adolescence. Risk factors for low BMD in patients with AN include onset of disease during adolescence, lower BMI, longer duration of illness, hypogonadotropic hypogonadism, low muscle mass, calcium intake less than 600 mg/day, and lower serum 25OH vitamin D levels 95, 97, 103, 104. In women with AN, bone formation is lower and bone resorption is higher than in controls , resulting in mean loss of BMD by dual-energy x-ray absorptiometry (DXA) of approximately 2.4% at the hip and 2.6% at the spine annually . Current or past use of medications known to affect bone density, including glucocorticoids, bisphosphonates, and anticonvulsants, were exclusion criteria for all groups. Twenty-eight healthy controls, 90–110% of IBW, with regular menses, were also studied. Women with anorexia nervosa fulfilled all DSM-IV (37) diagnostic criteria for anorexia nervosa. We conducted a cross-sectional study at a general clinical research center. Serum free testosterone in subjects receiving testosterone (black circles) or placebo (black squares).… Reduced GnRH pulsatility results in reduced LH and FSH pulsatility from the anterior pituitary, and consequently reduced estradiol secretion from the ovaries in women and testosterone secretion from the testes in men. Table 1 provides a summary of the hormone abnormalities in AN that are discussed in this review. In this article, we review the causes and treatment of endocrine abnormalities in AN. Low bone density and increased risk of fractures are also common complications. Our group has previously reported strong associations between change in free testosterone and change in surrogate markers of bone formation in adolescent girls with anorexia nervosa (50). Moreover, we have recently shown that low-dose testosterone replacement therapy increases bone density at the hip and radius in women with severe androgen deficiency due to hypopituitarism (43). Bone density is reduced in men with hypogonadism, and testosterone replacement results in reversal of the bone loss incurred. In contrast, the data regarding the effects of oral contraceptives on androgen levels in healthy women of reproductive age are congruent in that they clearly demonstrate decreases in free testosterone and DHEAS in healthy women of reproductive age (27–35). Linear regression models were constructed for total testosterone, free testosterone, and DHEAS on bone density and body composition variables; the results are shown in Table 3. We also investigated whether androgen and preandrogen levels were predictors of body composition and bone density. We hypothesized that bone formation would increase and depressive symptoms and spatial cognition would improve with short-term physiological testosterone administration. Anorexia nervosa (AN) is complicated by severe bone loss, cognitive function deficits, and a high prevalence of major depression. Males should be screened for AN if there is a history of weight loss, especially with co-existing psychiatric disorders or substance abuse, BMI below average for weight and height, symptoms of hypogonadism, or unexplained fragility fracture. The patients in this study have not followed-up, which limits our ability to determine if there has been additional improvement in symptoms or biochemical parameters. Arginine vasopressin, also known as antidiuretic hormone (ADH), is synthesized by the hypothalamus and stored in the posterior pituitary. Low levels of insulin, which are characteristic of states of undernutrition, might also have a role in GH resistance by downregulating hepatic GH receptor expression, as seen in human cell lines44. Multiple mechanisms have been proposed to contribute to GH resistance at the level of the liver and the resultant low circulating levels of IGF1, such as elevated fibroblast growth factor 21 (FGF21).
